Skip to main
NXTC

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NextCure Inc's recent acquisition of global rights to SIM0505 outside Greater China positions the company to potentially receive up to $745 million in upfront and milestone payments, along with tiered royalties that can reach double-digit percentages on net sales. The firm is also enhancing value for its antibody-drug conjugates (ADCs) and demonstrating promising preclinical data with robust anti-tumor activity and a favorable safety profile across multiple solid tumor models. Furthermore, NextCure is advancing its development pipeline with plans to initiate Phase I studies for SIM0505 in the U.S. after its ongoing dose-escalation studies in China.

Bears say

NextCure Inc has seen a significant reduction in its projected enterprise value, revised down to $37.5 million from a previous estimate of $75 million, which raises concerns regarding its financial stability and future growth potential. The company is also facing inherent risks associated with the clinical development of its therapies, which may fail to achieve anticipated results. Additionally, the substantial decrease in the price target, adjusted from $36 to $15, further reflects a negative outlook on the company's ability to deliver on its projected performance.

Nextcure (NXTC) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Nextcure (NXTC) has a Strong Buy consensus rating as of Jan 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.